# An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis

> **NCT07027527** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Apogee Therapeutics, Inc.** · enrollment: 86 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** APG777
- **DRUG:** APG990
- **DRUG:** Dupilumab

## Key facts

- **NCT ID:** NCT07027527
- **Lead sponsor:** Apogee Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07027527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07027527, "An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07027527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*